ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic.

New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion.



ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures

The purpose is to reduce the ongoing debt obligations.


ImmunoPrecise Announces Artificial Intelligence Collaboration with EVQLV to Accelerate Vaccine and Antibody Discovery for SARS-CoV-2 Coronavirus

EVQLV can filter antibody candidates with a higher probability of success against the SARS-CoV-2 Coronavirus.


ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program

IPA to develop innovative vaccines and coronavirus-neutralizing antibodies against SARS-CoV-2.


ImmunoPrecise integrates SGI-DNA's benchtop automated DNA printer to accelerate antibody discovery and manufacturing services

The BioXp 3200 will reduce the turnaround time for cloning activities in discovery and manufacturing projects

Items 1 to 6 of 81 total

Show per page